The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., GE Aerospace and ...

Although Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, Lilly has gained the lead in obesity prescriptions with Zepbound. The US company’s diabetes version of the ...

Zepbound won on all measures of effectiveness in a trial presented Monday at an obesity conference, spurring an average of 47% more weight loss over 72 weeks. Lilly, which funded the research, is ...

Zepbound’s performance in this direct comparison strengthens Lilly’s position in the rapidly growing weight loss medication market. The drug operates as a dual GIP and GLP-1 receptor agonist ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...

Although the CVS’s PBM dynamics may create near ... Lilly dominates the U.S. market for incretin analogues – a class of drugs that covers Zepbound and its type 2 diabetes drug Mounjaro.